Contact Us...

USF Breast Health
4001 E. Fletcher Ave.
2nd Floor Clinic
Tampa, FL  33613

Phone:  813-974-9220
Fax:  813-905-8835


Click on the following link for a Google Map to USF Breast Health:


Car Shows for Charity

USF Foundation Web Site


     The USF Breast Health Program is committed to using the latest technologies for treating breast cancer.  The following is a list of some of the technology currently in use.

Cryoablation Therapy

Cryoablation kills tumor cells by freezing them.  This may be an effective treatment for patients with invasive ductal breast cancer.

This is a clinical trial that is currently in progress.  Please click on the following link for more information:

Dr. John Cox, of Tampa Bay Breast Care Specialists, recently recorded a video of the Cryoablation procedure for PBS, which aired on March 18, 2011.  Please click on the following link to view it.

HALO Breast Pap Test

  • HALO is noninvasive, objective and repeatable, plus it's quick - just 5 minutes
  • HALO has been proven a safe and effective method to collect nipple aspirate fluid for analysis
  • Routine assessment with HALO will enable breast health monitoring and the ability to react to cellular changes early
     The HALO® Breast Pap Test is FDA approved for the collection of nipple aspirate fluid for cytological evaluation. The collected fluid can be used in the determination and/or differentiation of normal versus pre-malignant versus malignant cells.

Incorporating Halo into routine practice will enable physicians and patients to monitor cellular changes within breast ducts earlier, before they develop into larger, potentially cancerous lesions.

Xoft Axxent® eBx System for breast brachytherapy:

The Xoft Axxent® eBx System for breast brachytherapy is designed to simplify the radiation therapy procedure and increase accessibility to patients who are suitable candidates for partial-breast irradiation (PBI). Breast eBx with the Axxent System delivers a prescribed, targeted dose of radiation directly to the site where cancer recurrence is most likely. Compared to traditional radiotherapy, eBx requires fewer treatments and minimizes exposure to healthy tissue and organs, such as the ribs, lungs, heart and opposite breast (Reduced Dose to Heart and Lungs). Patients also experience low rates of serious complications and favorable cosmetic outcomes.

MammaPrint gene expression profiling system:  

   MammaPrint is a gene expression profiling system to assess the risk of cancer recurrence in patients with breast cancer. The system is based on the expression of 70 of the most informative genes in the tumor, quantified simultaneously to ensure a high degree of accuracy in determining the risk of breast cancer recurrence.  MammaPrint result are indicated for use by physicians as a prognostic marker in combination with other clinical information and laboratory tests. MammaPrint is also the first in vitro diagnostic multivariate index assay (IVDMIA) to acquire market clearance from the FDA.